Fluoguide AS (FLUO) - Total Liabilities
Based on the latest financial reports, Fluoguide AS (FLUO) has total liabilities worth Skr31.70 Million SEK (≈ $3.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fluoguide AS - Total Liabilities Trend (2018–2024)
This chart illustrates how Fluoguide AS's total liabilities have evolved over time, based on quarterly financial data. See FLUO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Fluoguide AS Competitors by Total Liabilities
The table below lists competitors of Fluoguide AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Wah Public Company Limited
BK:TWPC
|
Thailand | ฿3.06 Billion |
|
Advero Properties SOCIMI S.A.
MC:YADV
|
Spain | €8.49 Million |
|
Heron Therapeuti
NASDAQ:HRTX
|
USA | $237.08 Million |
|
Seouleaguer Co. Ltd
KQ:043710
|
Korea | ₩71.04 Billion |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
India | Rs17.64 Billion |
|
Daesung Holdin
KO:016710
|
Korea | ₩474.66 Billion |
|
Guizhou Zhongyida Co Ltd
SHG:900906
|
China | $899.58 Million |
|
Nanoform Finland Plc
HE:NANOFH
|
Finland | €12.56 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Fluoguide AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Fluoguide AS (FLUO) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -12.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fluoguide AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fluoguide AS (2018–2024)
The table below shows the annual total liabilities of Fluoguide AS from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr5.31 Million ≈ $571.76K |
-68.54% |
| 2023-12-31 | Skr16.89 Million ≈ $1.82 Million |
+362.46% |
| 2022-12-31 | Skr3.65 Million ≈ $393.01K |
-75.00% |
| 2021-12-31 | Skr14.61 Million ≈ $1.57 Million |
+18.47% |
| 2020-12-31 | Skr12.33 Million ≈ $1.33 Million |
+1671.70% |
| 2019-12-31 | Skr696.00K ≈ $74.90K |
+923.53% |
| 2018-12-31 | Skr68.00K ≈ $7.32K |
-- |
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more